<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085575</url>
  </required_header>
  <id_info>
    <org_study_id>CHM</org_study_id>
    <nct_id>NCT04085575</nct_id>
  </id_info>
  <brief_title>Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty</brief_title>
  <official_title>Efficacy of 1g Versus 2g Intra-auricular Tranexamic Acid in Postoperative Bleeding After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Montauban</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de Montauban</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting&#xD;
      fibrinolytic activities of plasmin and many studies confirms its effectiveness in decreasing&#xD;
      blood loss. The aim of this study was to observe postoperative bleeding with combined&#xD;
      intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of&#xD;
      tranexamic acid in adult patients undergoing unilateral total knee replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total knee arthroplasty (TKA) is widely used as an effective treatment for end-stage&#xD;
      osteoarthritis and other joint diseases of the knee and it improvements in surgical materials&#xD;
      and techniques have greatly increased its effectiveness. However, TKA is an orthopaedic&#xD;
      surgical method that has a substantial perioperative blood loss.&#xD;
&#xD;
      Classical methods for reducing blood loss and transfusion rate include the use of a pneumatic&#xD;
      tourniquet, intraoperative cell saver, hypotensive anesthesia, application of erythropoietin,&#xD;
      autologous blood transfusion, plugging of the femoral canal, cementing, drain clamping,&#xD;
      navigation and minimally invasive surgery.&#xD;
&#xD;
      Tranexamic acid (TXA) an antifibrinolytic that develops its anti-haemorrhagic action by&#xD;
      inhibiting fibrinolytic activities of plasmin has been used as an adjuvant to such measure&#xD;
      and many studies with a level of evidence confirms its effectiveness in decreasing blood&#xD;
      loss.&#xD;
&#xD;
      Fibrinolysis is stimulated by surgical trauma blood loss and TKA may be related to increased&#xD;
      fibrinolytic activity. TXA inhibits fibrinolysis by blocking the lysine-binding sites of&#xD;
      plasminogen to fibrin. Plasmin, bound to tranexamic acid, has a considerably diminished&#xD;
      activity with respect to fibrin compared to that of free plasmin. Also, it appears from&#xD;
      various studies that, in vivo, tranexamic acid at high doses exerts a braking activity on the&#xD;
      activation of the complement system. So, TXA reduces bleeding in the TKA and its functional&#xD;
      repercussion has also been confirmed in assays for various dosages and routes of&#xD;
      administration.&#xD;
&#xD;
      In the literature, efficacy of intra-articular TXA has also been confirmed, but what is the&#xD;
      right dosage is now unclear.&#xD;
&#xD;
      The aim of this study was to observe postoperative bleeding with combined intravenous and per&#xD;
      - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid&#xD;
      (Sanofi-AventisÂ® Gentilly, France).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>They were assigned in two groups: The G1 group received 1 g of intra-articular tranexamic acid (TXA) and the G2 group received 2 g of intra-articular tranexamic acid. Both groups received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007 (Microsoft Corporation, Seattle, Washington, USA).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss in postoperative drainage.</measure>
    <time_frame>Blood loss in 24 hours postoperative drainage</time_frame>
    <description>The primary endpoint was the bleeding represented by blood loss in postoperative drainage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in hematocrit levels</measure>
    <time_frame>change in hematocrit levels at 24 and 72 hours</time_frame>
    <description>The secondary outcomes were the change in hematocrit levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in hemoglobin levels</measure>
    <time_frame>change in hemoglobin levels at 24 and 72 hours</time_frame>
    <description>The secondary outcomes were the change in hemoglobin levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Hemorrhage</condition>
  <arm_group>
    <arm_group_label>tranexamic acid - The G1 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The G1 group received 1 g of intra-articular tranexamic acid (TXA). The G1 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tranexamic acid - The G2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The G2 group received 2 g of intra-articular tranexamic acid (TXA). The G2 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acide Tranexamique</intervention_name>
    <description>Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.</description>
    <arm_group_label>tranexamic acid - The G1 group</arm_group_label>
    <arm_group_label>tranexamic acid - The G2 group</arm_group_label>
    <other_name>Exacyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Adult patients undergoing unilateral total knee replacement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of consent&#xD;
&#xD;
          -  Tranexamic acid allergy&#xD;
&#xD;
          -  Coagulopathy (preoperative platelet count &lt;150,000 / mm3, INR [international&#xD;
             normalized ratio]&gt; 1.4, or prolonged partial thromboplastin time&gt; 1.4 times normal),&#xD;
&#xD;
          -  History of arterial or venous thromboembolic disease (cerebrovascular accident, deep&#xD;
             vein thrombosis or pulmonary thromboembolism),&#xD;
&#xD;
          -  Hematological disorder (a hematopoietic, hemorrhagic or thrombogenic disease),&#xD;
&#xD;
          -  Retinopathy (severe limitation of the field of vision and / or color distortion),&#xD;
&#xD;
          -  Refusal to receive blood products&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of convulsions&#xD;
&#xD;
          -  Participation in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Edmundo Pereira de Souza Neto</name>
      <address>
        <city>Montauban</city>
        <state>Tarn Et Garonne</state>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The aim of our study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

